1AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$267.20 |
| 52 Week High | US$283.85 |
| 52 Week Low | US$201.00 |
| Beta | 0.58 |
| 1 Month Change | 9.06% |
| 3 Month Change | 28.22% |
| 1 Year Change | 4.25% |
| 3 Year Change | 37.08% |
| 5 Year Change | n/a |
| Change since IPO | 26.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1AMGN | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 5.2% | 1.7% | 1.5% |
| 1Y | 4.3% | -11.0% | 20.2% |
Return vs Industry: 1AMGN exceeded the Italian Biotechs industry which returned -9.8% over the past year.
Return vs Market: 1AMGN underperformed the Italian Market which returned 17.6% over the past year.
Price Volatility
| 1AMGN volatility | |
|---|---|
| 1AMGN Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: 1AMGN has not had significant price volatility in the past 3 months.
Volatility Over Time: 1AMGN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 25,200 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Amgen Inc. Fundamentals Summary
| 1AMGN fundamental statistics | |
|---|---|
| Market cap | €145.46b |
| Earnings (TTM) | €7.56b |
| Revenue (TTM) | €25.20b |
19.2x
P/E Ratio5.8x
P/S RatioIs 1AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AMGN income statement (TTM) | |
|---|---|
| Revenue | US$26.58b |
| Cost of Revenue | US$6.83b |
| Gross Profit | US$19.75b |
| Other Expenses | US$11.77b |
| Earnings | US$7.98b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 31, 2023
| Earnings per share (EPS) | 14.92 |
| Gross Margin | 74.29% |
| Net Profit Margin | 30.02% |
| Debt/Equity Ratio | 907.6% |
How did 1AMGN perform over the long term?
See historical performance and comparison